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Purpose
The clinical relevance of residual low level viremia
(LLV) in patients on steady HAART is debated. Simi-
larly the clinical usefulness of HIV-RNA cut-offs lower
than 50 copies/ml is questioned. Aim of this study was
to analyze the dynamics of LLV in patients on HAART
by means of a high resolution test for HIV-RNA.
Methods
This is a prospective, single-center, cohort study in patients
on stable HAART (mean time on HAART 109 months, SD
28). All patients with a confirmed viremia <50 copies/ml
were enrolled. Patients were monitored prospectively with
determinations of HIV-RNA every 4 months performed
with an enhanced PCR test with a lower limit of detection
of 3 copies/ml. ITT analysis is reported.
Results
A total of 505 patients (78% males) with a mean age of
45.6 years (SD 7.6) were enrolled. At baseline the mean
CD4 count was 667 cells/µl (SD 268) and VL was < 3
copies/ml in 73.9% and between 3 and 50 copies/ml in
the remaining 26.1% of cases. Over the following 8
months period, patients with a baseline VL < 3 copies/ml
presented a stable HIV-RNA below this threshold in
72.8% of cases, a level between 3 and 50 copies/ml in
27.2% of cases while no patient steadily rebounded above
the 50 copies/ml threshold. On the contrary, patients
with a baseline HIV-RNA between 3 and 50 copies/ml, in
the follow-up, presented a stable VL < 3 copies/ml in
43.8% of cases, a VL between 3 and 50 copies/ml in
53.1% of cases, while 3.1% of patients steadily rebounded
above the 50 copies/ml threshold (P < 0.0001). In the
multivariate analysis the only variable significantly asso-
ciated with viral dynamics was the third drug in the
HAART regimen. A steady VL < 3 copies/ml, a VL
between 3 and 50 copies/ml or a steady VL > 50 copies/
ml was detected, respectively, in 71.8%; 27.7% and 0.6%
of NNRTI-treated patients, while the same figures for PI-
treated subjects were 56.2%; 42.9% and 1.0% (P = 0.029).
Conclusions
The presence of a LLV is associated to a low risk of vir-
ological failure; however, in selected patients it may be
indicative of effective virus replication leading to virolo-
gical rebound. Patients treated with a NNRTI-based
HAART compared to those receiving a PI-based regi-
men show a statistically significant more pronounced
and steady control of viral replication. Further, pro-
longed studies are needed to assess the clinical relevance
of residual LLV and eventually define new cut-off values
predictive of a better control of virus replication.
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